
Gossamer Bio Reports Final Results of Convertible Notes Exchange Offer and Consent Solicitation
Gossamer Bio Announces Final Results of Convertible Notes Exchange Offer, Strengthening Financial Position Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on advancing therapies for pulmonary hypertension, has announced the final results of its previously disclosed exchange offer involving its…












